SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010; 16: 338346.
  • 2
    Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults. Am J Gastroenterol. 2010; 105: 501523
  • 3
    Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133: 412422.
  • 4
    Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011; 9: 483489.
  • 5
    D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132: 763186.
  • 6
    Daperno M, Sostegni R, Pera A, et al. The role of endoscopic assessment in ulcerative colitis in the era of infliximab. Dig Liver Dis. 2008; 40( suppl 2): S220224.
  • 7
    Kane S, Lu F, Kornbluth A, et al. Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2009; 15: 796800.
  • 8
    Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997; 92: 18671871.
  • 9
    Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005; 54: 960965.
  • 10
    Vecchi M, Meucci G, Gionchetti P, et al. Comparison of oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized, multicenter italian study. Aliment Pharm Ther. 2001; 15: 251256.
  • 11
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317: 16251629.
  • 12
    Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008; 14: 16601666.
  • 13
    Kornbluth A, Kamm MA, Lichtenstein GR, et al. Symptomatic resolution is an inadequate predictor of complete colonic. Mucosal healing in mild-to-moderate ulcerative colitis. Gastroenterology. 2007; 132: A506 [abstract].
  • 14
    Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007; 5: 95102.
  • 15
    Hanauer SB. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis. 1998; 4: 7983.
  • 16
    Pokrotnieks J, Marlicz K, Paradowski L, et al. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther. 2000; 14: 11911198.
  • 17
    Higgins PD, Schwartz M, Mapili J, et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol. 2005; 100: 355361.
    Direct Link:
  • 18
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954; 2: 375378.
  • 19
    Beattie RM, Nicholls SW, Domizio P, et al. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Pediatr Gastroenterol Nutr. 1996; 22: 373379.
  • 20
    Oshitani N, Matsumoto T, Jinno Y, et al. Prediction of short-term outcome for patients with active ulcerative colitis. Dig Dis Sci. 2000; 45: 982986.
  • 21
    Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis. 2010; 16: 19051911.
  • 22
    Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001; 120: 1320.
  • 23
    Riley SA, Mani V, Goodman MJ, et al. Why do patients with ulcerative colitis relapse? Gut. 1990; 31: 179183.
  • 24
    Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991; 32: 174178.
  • 25
    Leo S, Leandro G, Di Matteo G, et al. Ulcerative colitis in remission: it is possible to predict the risk of relapse? Digestion. 1989; 44: 217221.
  • 26
    Moum B, Ekbom A, Vatn MH, et al. Clinical course during the 1st year after diagnosis in ulceratve colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990–93. Scand J Gastroenterol. 1997; 32: 10051012.
  • 27
    Sewitch MJ, Abrahamowicz M. Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003; 98: 15351544.
    Direct Link:
  • 28
    Bernal I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci. 2006; 51: 21652169.
  • 29
    Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003; 114: 3943.
  • 30
    Shale MJ. Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18: 191198.
  • 31
    Kane SV, Cohen RD. Aikens JE, et al. Prevalence of nonadherence with maintenance mesalarnine in quiescent ulcerative colitis. Am J Gastroenterol. 2001; 96: 29292933.
    Direct Link:
  • 32
    Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009; 137: 19341943.